Patents by Inventor Diego DOLCETTA

Diego DOLCETTA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADMINISTRATION OF mTOR INHIBITORS INTO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20230133251
    Abstract: The present invention relates to lipid vesicles containing at least one mTOR inhibitor for use in the treatment or prevention of a disease of the central nervous system. The invention also relates to a pharmaceutical composition comprising said lipid vesicles, preferably in the form of a solution, emulsion or suspension.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 4, 2023
    Inventor: Diego Dolcetta
  • INTRATHECAL ADMINISTRATION, PREFERABLY INTRAVENTRICULAR, OF MTOR INHIBITORS FOR THE THERAPY OF SOME NEURODEGENERATIVE, NEUROINFLAMMATORY AND NEURO-ONCOLOGIC DISEASES
    Publication number: 20160324770
    Abstract: The invention relates to the use of inhibitors of the enzyme mTOR kinase (mammalian target of rapamycin) in the treatment of neuro-oncologic diseases, in particular tuberous sclerosis, neurodegenerative diseases, in particular Alzheimer's disease, and neuroinflammatory diseases, in particular multiple sclerosis and primary progressive aphasia, via intrathecal, or preferably intraventricular, administration of said inhibitors.
    Type: Application
    Filed: July 21, 2016
    Publication date: November 10, 2016
    Inventor: Diego DOLCETTA
  • INTRATHECAL ADMINISTRATION OF MTOR INHIBITORS FOR THE THERAPY OF NEURODEGENERATIVE, NEUROINFLAMMATORY AND NEUROONCOLOGIC DISEASES
    Publication number: 20150132397
    Abstract: The invention relates to the use of inhibitors of the enzyme mTOR kinase (mammalian target of rapamycin) in the treatment of neuro-oncologic diseases, in particular tuberous sclerosis, neurodegenerative diseases, in particular Alzheimer's disease, and neuroinflammatory diseases, in particular multiple sclerosis and primary progressive aphasia, via intrathecal, or preferably intraventricular, administration of said inhibitors.
    Type: Application
    Filed: May 10, 2013
    Publication date: May 14, 2015
    Inventor: Diego DOLCETTA